扩大细胞和基因疗法的生产能力:采访 Julie G Allickson。

IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-05-01 Epub Date: 2023-05-11 DOI:10.2217/rme-2023-0057
Julie G Allickson
{"title":"扩大细胞和基因疗法的生产能力:采访 Julie G Allickson。","authors":"Julie G Allickson","doi":"10.2217/rme-2023-0057","DOIUrl":null,"url":null,"abstract":"<p><p>Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 5","pages":"373-375"},"PeriodicalIF":2.4000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expanding the manufacturing capacity for cell and gene therapies: an interview with Julie G Allickson.\",\"authors\":\"Julie G Allickson\",\"doi\":\"10.2217/rme-2023-0057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.</p>\",\"PeriodicalId\":21043,\"journal\":{\"name\":\"Regenerative medicine\",\"volume\":\"18 5\",\"pages\":\"373-375\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regenerative medicine\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.2217/rme-2023-0057\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.2217/rme-2023-0057","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

摘要

Julie G Allickson 博士是梅奥诊所(明尼苏达州、佛罗里达州和亚利桑那州)梅奥诊所再生生物治疗中心的迈克尔-S 和玛丽-苏-香农家族主任,也是再生生物治疗中心生物制造和产品开发奥托-布雷默信托主任。Allickson博士在再生医学、细胞疗法和监管事务方面拥有超过25年的经验,他领导该中心转向生物制造,确保新发现能够成功地应用于临床,并最终实现商业化。该中心正在组建一支行业经验丰富的团队,负责生物制造的所有支柱工作,为梅奥诊所的临床研究人员和主要研究人员提供支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Expanding the manufacturing capacity for cell and gene therapies: an interview with Julie G Allickson.

Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Regenerative medicine
Regenerative medicine 医学-工程:生物医学
CiteScore
4.20
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.
期刊最新文献
Bone marrow aspirate concentrate for the treatment of fifth metatarsal head stress fracture: a case report. Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1